An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid
Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) wi...
Main Authors: | Charles Dupin, Jade Sutter, Samuel Amintas, Marie-Alix Derieppe, Magalie Lalanne, Soule Coulibaly, Joris Guyon, Thomas Daubon, Julian Boutin, Jean-Marc Blouin, Emmanuel Richard, François Moreau-Gaudry, Aurélie Bedel, Véronique Vendrely, Sandrine Dabernat |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/17/4244 |
Similar Items
-
In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy
by: Junko Takahashi, et al.
Published: (2021-09-01) -
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma
by: Niklas Benedikt Pepper, et al.
Published: (2024-01-01) -
Effect of 5-aminolevulinic Acid on Mitochondrial Activity
by: Yuliya V. Markina, et al.
Published: (2023-12-01) -
5-Aminolevulinic acid: A matter of life and caveats
by: Etelvino J.H. Bechara, et al.
Published: (2021-09-01) -
5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges
by: Yoshinori Harada, et al.
Published: (2022-06-01)